Biomatter raises $18m for custom enzyme design
Biomatter’s Series A supports a new Vilnius facility and US expansion for its computational and laboratory enzyme-design platform.

Designing an enzyme is only part of the job. It also needs to perform the intended reaction in a physical process.
What happened
Vilnius-based Biomatter closed an $18m Series A led by Astanor, with UVC Partners, Inventure and Metaplanet participating. It combines computational design with laboratory testing to develop enzymes for specific reactions. The funding supports a new Vilnius facility and US commercial expansion; the facility is scheduled to open in 2027.
Why it matters
Enzymes influence the cost and feasibility of processes used in diagnostics, pharmaceuticals and industrial manufacturing. Combining design and testing connects model output to the properties customers need.
The bigger picture
AI tools for biology increasingly depend on experimental feedback. The laboratory helps establish which designs work and generates information for the next design cycle.
